Shen, Yihui http://orcid.org/0000-0001-8490-6413
Dinh, Hoang V. http://orcid.org/0000-0002-3861-357X
Cruz, Edward R.
Chen, Zihong http://orcid.org/0000-0002-1554-1649
Bartman, Caroline R.
Xiao, Tianxia http://orcid.org/0000-0003-2324-7949
Call, Catherine M. http://orcid.org/0000-0002-2719-2482
Ryseck, Rolf-Peter
Pratas, Jimmy
Weilandt, Daniel
Baron, Heide
Subramanian, Arjuna
Fatma, Zia
Wu, Zong-Yen
Dwaraknath, Sudharsan
Hendry, John I.
Tran, Vinh G.
Yang, Lifeng
Yoshikuni, Yasuo http://orcid.org/0000-0002-8372-640X
Zhao, Huimin http://orcid.org/0000-0002-9069-6739
Maranas, Costas D. http://orcid.org/0000-0002-1508-1398
Wühr, Martin http://orcid.org/0000-0002-0244-8947
Rabinowitz, Joshua D. http://orcid.org/0000-0002-1247-4727
Funding for this research was provided by:
U.S. Department of Energy (DE-SC0018260, DE-SC0018420, DE-SC0018260, DE-SC0018420, DE-SC0018260, DE-SC0018420, DE-SC0018260, DE-SC0018420, DE-SC0018260)
Ludwig Institute for Cancer Research
National Science Foundation
U.S. Department of Health & Human Services | National Institutes of Health (35GM128813, P30CA072720, K99CA273517)
U.S. Department of Health & Human Services | National Institutes of Health
Damon Runyon Cancer Research Foundation
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 24 September 2023
Accepted: 5 February 2024
First Online: 6 March 2024
Competing interests
: J.D.R. is a paid adviser and/or stockholder in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Faeth Therapeutics and Empress Therapeutics; a paid consultant of Pfizer; a founder and stockholder in Marea Therapeutics and a founder, director and stockholder of Farber Partners, Raze Therapeutics and Sofro Pharmaceuticals. The other authors declare no conflicts of interest.